Navigation Links
Inhibitors of shuttle molecule show promise in acute leukemia
Date:6/19/2012

  • An estimated 10,200 Americans will die of acute myeloid leukemia (AML) in 2012, so new ways of treating the disease are needed.
  • This study uses a novel class of experimental drugs to halt a process that helps AML cells develop and survive.
  • The findings show that the agent is promising and should be considered for clinical trials testing.

COLUMBUS, Ohio A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people with acute leukemia, according to a study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The agents, called KPT-SINEs (selective inhibitors of nuclear export), target a transport protein called CRM1. Using acute myeloid leukemia (AML) cells and an animal model, the researchers showed that these agents inhibited leukemia-cell proliferation, arrested cell division, and induced cell death and differentiation.

In the animal model of AML, KPT-SINEs described by the researchers as one of the most advanced agents in pre-clinical development extended survival by 46 percent compared with controls.

KPT-SINEs were particularly effective when the leukemia cells also had mutations in the tumor-suppressor gene NPM1, which are present in about one-third of all adult AML.

The findings were published online in the journal Blood.

"Our study suggests that these agents might be an effective therapy for AML, particularly for patients with NPM1 mutations," says principal investigator Dr. Ramiro Garzon, assistant professor of medicine and a researcher with the OSUCCC James Molecular Biology and Cancer Genetics Program.

"We hope to start a phase I trial using one of these agents soon and to pursue further preclinical studies using this drug in combination with other current chemotherapies," Garzon says.

CRM1 normally transports molecules out of the cell nucleus to the surrounding cytoplasm. In acute leukemia cells, the molecule carries tumor-suppressor, apoptotic and other protective proteins out of the nucleus, thereby contributing to leukemia development. Karyopharm Therapeutics, Inc., developed KPT-SINEs. This study also showed that these agents:

  • Reduce the amount of CRM1 protein in the nucleus and increase the amount of tumor-suppressor protein such as p53 and NPM1 in AML cells.
  • Strongly down-regulate FLT3 and KIT, oncogenes that are commonly overexpressed in AML.
  • Increase survival in a leukemia animal model, with treated mice living an average of 39 days versus 27 days for untreated animals.

'/>"/>
Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Molecule movements that make us think
2. Prions in the brain eliminated by homing molecules
3. Researchers identify a life-and-death molecule on chronic leukemia cells
4. Early Study Finds Some Promise for Lung Cancer Vaccine
5. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
6. Nonsurgical Method to Measure Brain Pressure Shows Promise
7. Immunotherapy for elderly cancer patients finds new promise in drug combination
8. Experimental Pill for Multiple Sclerosis Shows Promise
9. Mechanical tissue resuscitation technology shows promise
10. Brain Tumor Vaccine Shows Promise in Early Trial
11. New Method to Reveal Alzheimers Marker Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... , ... Nissar A. Darmani, PhD, has been awarded a record WesternU research ... and vomiting. Dr. Darmani is Associate Dean of Basic Medical Sciences in the ... from the National Cancer Institute (NCI) arm of the National Institutes of Health (NIH). ...
(Date:9/25/2017)... ... September 25, 2017 , ... Introducing Panther, the revolutionary new iPhone ... crowdfunding platform Kickstarter seeking support for the #WarOnGrime. , Fact: iPhones are ... All shockingly revolting, yet true. The Panther iPhone cases are the first weapon in ...
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that two of its ... of bioassays at two upcoming conferences. , At the BEBPA 10th Annual Bioassay ...
(Date:9/25/2017)... ... September 25, 2017 , ... PITTSBURGH...An inventor, from Richmond Hill, Ga., thought ... hospitals and medical facilities, so he invented the COMPLETE PATIENT CHART. , The COMPLETE ... doing so, it offers an improved alternative to paper charts and clipboards. As a ...
(Date:9/25/2017)... OH (PRWEB) , ... September 25, 2017 , ... METTLER ... take place October 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers ... information dealing with today's mass calibration technologies and help with planning for the future ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/7/2017)... -- Eli Lilly and Company (NYSE: LLY ... more efficiently focus resources on developing new medicines ... reductions, including those from a U.S. voluntary early ... positions. With the streamlining efforts ... $500 million that will begin to be realized ...
(Date:9/7/2017)... 7, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Morgan ... the Grand Hyatt hotel in New York.  Zimmer Biomet ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology: